Ameet Mallik wraps a $435M com­mer­cial deal short­ly af­ter tak­ing helm at ADC

Two months in as the new CEO of the Eu­ro­pean-based biotech ADC Ther­a­peu­tics, Ameet Mallik can take cred­it for a sub­stan­tial re­gion­al li­cens­ing pact cov­er­ing its first com­mer­cial ther­a­peu­tic.

Stock­holm-based So­bi has stepped up with $55 mil­lion in cash and an­oth­er $50 mil­lion wait­ing on the ta­ble for an ex­pect­ed Eu­ro­pean Com­mis­sion ap­proval of Zyn­lon­ta, ADC’s CD19-tar­get­ed an­ti­body-drug con­ju­gate, for dif­fuse large B-cell lym­phoma. So­bi is al­so an­te­ing up $330 mil­lion for mile­stones, in­clud­ing sales, as it gets the mar­ket­ing li­cense for the drug out­side the US, Chi­na, Japan and Sin­ga­pore.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER